Ingrid Delaet's most recent trade in Neurocrine Biosciences, Inc. was a trade of 34,153 Stock Option done . Disclosure was reported to the exchange on Feb. 12, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 34,153 | 34,153 | - | - | Stock Option | |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 6,401 | 6,401 | - | - | Restricted Stock Unit | |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2025 | 1,401 | 5,485 (0%) | 0% | 0 | Common Stock | |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2025 | 1,401 | 4,203 | - | - | Restricted Stock Unit | |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2025 | 1,358 | 4,800 (0%) | 0% | 0 | Common Stock | |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2025 | 1,358 | 2,718 | - | - | Restricted Stock Unit | |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Sale of securities on an exchange or to another person at price $ 116.72 per share. | 12 Feb 2025 | 755 | 4,730 (0%) | 0% | 116.7 | 88,125 | Common Stock |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Sale of securities on an exchange or to another person at price $ 116.69 per share. | 12 Feb 2025 | 716 | 4,084 (0%) | 0% | 116.7 | 83,549 | Common Stock |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 1,179 | 0 | - | - | Restricted Stock Unit | |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 1,179 | 4,065 (0%) | 0% | 0 | Common Stock | |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 801 | 3,308 (0%) | 0% | 0 | Common Stock | |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 801 | 801 | - | - | Restriced Stock Unit | |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Sale of securities on an exchange or to another person at price $ 149.29 per share. | 31 Jan 2025 | 623 | 3,442 (0%) | 0% | 149.3 | 93,008 | Common Stock |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Sale of securities on an exchange or to another person at price $ 153.05 per share. | 31 Jan 2025 | 422 | 2,886 (0%) | 0% | 153.0 | 64,587 | Common Stock |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Sale of securities on an exchange or to another person at price $ 138.10 per share. | 31 Dec 2024 | 272 | 2,507 (0%) | 0% | 138.1 | 37,563 | Common Stock |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 79.02 per share. | 31 Dec 2024 | 272 | 2,779 (0%) | 0% | 79.0 | 21,493 | Common Stock |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 272 | 2,718 | - | - | Non-Qualified Stock Option | |
Neurocrine Biosciences, Inc. | Delaet Ingrid | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 79.02 per share. | 17 Dec 2024 | 1,091 | 3,598 (0%) | 0% | 79.0 | 86,211 | Common Stock |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Dec 2024 | 1,091 | 2,990 | - | - | Non-Qualified Stock Option | |
Neurocrine Biosciences, Inc. | Delaet Ingrid | Chief Regulatory Officer | Sale of securities on an exchange or to another person at price $ 135.00 per share. | 17 Dec 2024 | 1,091 | 2,507 (0%) | 0% | 135 | 147,285 | Common Stock |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Sale of securities on an exchange or to another person at price $ 150.08 per share. | 13 Aug 2024 | 4,100 | 2,507 (0%) | 0% | 150.1 | 615,333 | Common Stock |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Sale of securities on an exchange or to another person at price $ 150.13 per share. | 13 Aug 2024 | 3,043 | 6,607 (0%) | 0% | 150.1 | 456,847 | Common Stock |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Aug 2024 | 3,043 | 22,049 | - | - | Non-Qualified Stock Option | |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 103.52 per share. | 13 Aug 2024 | 3,043 | 9,650 (0%) | 0% | 103.5 | 315,011 | Common Stock |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 79.02 per share. | 06 Aug 2024 | 273 | 6,880 (0%) | 0% | 79.0 | 21,572 | Common Stock |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Aug 2024 | 273 | 4,081 | - | - | Non-Qualified Stock Option | |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Sale of securities on an exchange or to another person at price $ 147.70 per share. | 06 Aug 2024 | 273 | 6,607 (0%) | 0% | 147.7 | 40,322 | Common Stock |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Sale of securities on an exchange or to another person at price $ 150.00 per share. | 16 Jul 2024 | 1,557 | 7,507 (0%) | 0% | 150 | 233,550 | Common Stock |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 103.52 per share. | 16 Jul 2024 | 1,557 | 9,064 (0%) | 0% | 103.5 | 161,181 | Common Stock |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jul 2024 | 1,557 | 25,092 | - | - | Non-Qualified Stock Option | |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Sale of securities on an exchange or to another person at price $ 150.04 per share. | 16 Jul 2024 | 900 | 6,607 (0%) | 0% | 150.0 | 135,036 | Common Stock |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jul 2024 | 400 | 26,649 | - | - | Non-Qualified Stock Option | |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Sale of securities on an exchange or to another person at price $ 150.10 per share. | 16 Jul 2024 | 400 | 7,507 (0%) | 0% | 150.1 | 60,041 | Common Stock |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 103.52 per share. | 16 Jul 2024 | 400 | 7,907 (0%) | 0% | 103.5 | 41,408 | Common Stock |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2024 | 272 | 4,354 | - | - | Non-Qualified Stock Option | |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 79.02 per share. | 01 Jul 2024 | 272 | 7,779 (0%) | 0% | 79.0 | 21,493 | Common Stock |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Sale of securities on an exchange or to another person at price $ 138.11 per share. | 01 Jul 2024 | 272 | 7,507 (0%) | 0% | 138.1 | 37,566 | Common Stock |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 79.02 per share. | 31 May 2024 | 273 | 7,780 (0%) | 0% | 79.0 | 21,572 | Common Stock |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 May 2024 | 273 | 4,626 | - | - | Non-Qualified Stock Option | |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Sale of securities on an exchange or to another person at price $ 136.55 per share. | 31 May 2024 | 273 | 7,507 (0%) | 0% | 136.5 | 37,278 | Common Stock |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Sale of securities on an exchange or to another person at price $ 140.55 per share. | 06 May 2024 | 273 | 7,507 (0%) | 0% | 140.5 | 38,370 | Common Stock |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 May 2024 | 273 | 4,899 | - | - | Non-Qualified Stock Option | |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 79.02 per share. | 06 May 2024 | 273 | 7,780 (0%) | 0% | 79.0 | 21,572 | Common Stock |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Sale of securities on an exchange or to another person at price $ 137.30 per share. | 01 Apr 2024 | 272 | 7,507 (0%) | 0% | 137.3 | 37,346 | Common Stock |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 272 | 5,172 | - | - | Non-Qualified Stock Option | |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 79.02 per share. | 01 Apr 2024 | 272 | 7,779 (0%) | 0% | 79.0 | 21,493 | Common Stock |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Mar 2024 | 5,000 | 27,049 | - | - | Non-Qualified Stock Option | |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 103.52 per share. | 21 Mar 2024 | 5,000 | 12,507 (0%) | 0% | 103.5 | 517,600 | Common Stock |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Sale of securities on an exchange or to another person at price $ 145.06 per share. | 21 Mar 2024 | 5,000 | 7,507 (0%) | 0% | 145.1 | 725,320 | Common Stock |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Mar 2024 | 3,000 | 4,367 | - | - | Non-Qualified Stock Option | |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 106.02 per share. | 13 Mar 2024 | 3,000 | 10,507 (0%) | 0% | 106.0 | 318,060 | Common Stock |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Sale of securities on an exchange or to another person at price $ 140.14 per share. | 13 Mar 2024 | 3,000 | 7,507 (0%) | 0% | 140.1 | 420,419 | Common Stock |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Sale of securities on an exchange or to another person at price $ 140.03 per share. | 08 Mar 2024 | 1,800 | 7,507 (0%) | 0% | 140.0 | 252,053 | Common Stock |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Mar 2024 | 1,800 | 7,567 | - | - | Non-Qualified Stock Option | |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 106.02 per share. | 08 Mar 2024 | 1,800 | 9,307 (0%) | 0% | 106.0 | 190,836 | Common Stock |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Mar 2024 | 200 | 7,367 | - | - | Non-Qualified Stock Option | |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Sale of securities on an exchange or to another person at price $ 140.00 per share. | 08 Mar 2024 | 200 | 7,507 (0%) | 0% | 140 | 28,000 | Common Stock |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 106.02 per share. | 08 Mar 2024 | 200 | 7,707 (0%) | 0% | 106.0 | 21,204 | Common Stock |
Neurocrine Biosciences, Inc. | Delaet Ingrid | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 2,500 | 9,761 | - | - | Non-Qualified Stock Option | |
Neurocrine Biosciences, Inc. | Delaet Ingrid | Chief Regulatory Officer | Sale of securities on an exchange or to another person at price $ 135.64 per share. | 28 Feb 2024 | 2,500 | 7,507 (0%) | 0% | 135.6 | 339,104 | Common Stock |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 79.02 per share. | 28 Feb 2024 | 2,500 | 10,007 (0%) | 0% | 79.0 | 197,550 | Common Stock |
Neurocrine Biosciences, Inc. | Delaet Ingrid | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 79.02 per share. | 28 Feb 2024 | 2,500 | 10,007 (0%) | 0% | 79.0 | 197,550 | Common Stock |
Neurocrine Biosciences, Inc. | Delaet Ingrid | Chief Regulatory Officer | Sale of securities on an exchange or to another person at price $ 134.62 per share. | 28 Feb 2024 | 2,500 | 7,507 (0%) | 0% | 134.6 | 336,550 | Common Stock |
Neurocrine Biosciences, Inc. | Delaet Ingrid | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 2,500 | 7,261 | - | - | Non-Qualified Stock Option | |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 1,544 | 5,717 | - | - | Non-Qualified Stock Option | |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 79.02 per share. | 28 Feb 2024 | 1,544 | 9,051 (0%) | 0% | 79.0 | 122,007 | Common Stock |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Sale of securities on an exchange or to another person at price $ 136.00 per share. | 28 Feb 2024 | 1,544 | 7,507 (0%) | 0% | 136 | 209,984 | Common Stock |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 79.02 per share. | 28 Feb 2024 | 273 | 7,780 (0%) | 0% | 79.0 | 21,572 | Common Stock |
Neurocrine Biosciences, Inc. | Delaet Ingrid | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 273 | 5,444 | - | - | Non-Qualified Stock Option | |
Neurocrine Biosciences, Inc. | Delaet Ingrid | Chief Regulatory Officer | Sale of securities on an exchange or to another person at price $ 135.51 per share. | 28 Feb 2024 | 273 | 7,507 (0%) | 0% | 135.5 | 36,994 | Common Stock |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 28,161 | 28,161 | - | - | Stock Option | |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 5,604 | 5,604 | - | - | Restricted Stock Unit | |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Sale of securities on an exchange or to another person at price $ 133.03 per share. | 13 Feb 2024 | 716 | 7,507 (0%) | 0% | 133.0 | 95,253 | Common Stock |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Sale of securities on an exchange or to another person at price $ 139.77 per share. | 31 Jan 2024 | 623 | 6,865 (0%) | 0% | 139.8 | 87,077 | Common Stock |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Sale of securities on an exchange or to another person at price $ 141.94 per share. | 31 Jan 2024 | 422 | 6,309 (0%) | 0% | 141.9 | 59,899 | Common Stock |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Sale of securities on an exchange or to another person at price $ 107.52 per share. | 28 Aug 2023 | 1,431 | 5,931 (0%) | 0% | 107.5 | 153,861 | Common Stock |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Sale of securities on an exchange or to another person at price $ 107.42 per share. | 21 Aug 2023 | 1,404 | 4,645 (0%) | 0% | 107.4 | 150,820 | Common Stock |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 33,771 | 33,771 | - | - | Stock Option | |
Neurocrine Biosciences, Inc. | Ingrid Delaet | Chief Regulatory Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 5,434 | 5,434 | - | - | Restricted Stock Unit |